Literature DB >> 19647470

Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.

Radu Constantinescu1, Lars Rosengren, Bo Johnels, Henrik Zetterberg, Bjorn Holmberg.   

Abstract

Cerebrospinal fluid (CSF) levels of neurofilament light protein (NFL), a marker of neuronal damage, are normal in Parkinson's disease (PD) but elevated in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). Therefore, CSF NFL can help differentiate between PD on one hand and MSA/PSP on the other. In the present study of 10 patients with PD, 21 with MSA, 14 with PSP, 11 with corticobasal degeneration (CBD), and 59 healthy controls, this previous observation is confirmed and also extended to include CBD by showing that similarly high CSF NFL levels are seen not only in MSA and PSP but also in CBD. CSF levels of glial fibrillary acidic protein (GFAP), a protein expressed mainly in fibrillary astrocytes, were similar in all investigated groups. In addition, consecutive analyses of CSF NFL and CSF GFAP levels showed relatively stable levels over time in all the investigated parkinsonian disorders, suggesting that the rate of neuronal degeneration is rather constant over time. Our results suggest that measurements of CSF NFL but not GFAP can be useful in the differential diagnosis of PD versus atypical parkinsonian disorders (APD). However they do not help differentiate between the different APD. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19647470     DOI: 10.1016/j.parkreldis.2009.07.007

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  31 in total

1.  Novel CSF biomarkers for frontotemporal lobar degenerations.

Authors:  W T Hu; A Chen-Plotkin; M Grossman; S E Arnold; C M Clark; L M Shaw; L McCluskey; L Elman; H I Hurtig; A Siderowf; V M-Y Lee; H Soares; J Q Trojanowski
Journal:  Neurology       Date:  2010-11-03       Impact factor: 9.910

2.  Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.

Authors:  Xiaohui Hu; Yan Yang; Daokai Gong
Journal:  Neurol Sci       Date:  2016-11-28       Impact factor: 3.307

Review 3.  Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis.

Authors:  Shengri Cong; Chunchen Xiang; Hailong Wang; Shuyan Cong
Journal:  J Neurol       Date:  2020-03-11       Impact factor: 4.849

4.  Multiple system atrophy: current and future approaches to management.

Authors:  Olivier Flabeau; Wassilios G Meissner; François Tison
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

5.  CSF biomarkers and clinical progression of Parkinson disease.

Authors:  Sara Hall; Yulia Surova; Annika Öhrfelt; Henrik Zetterberg; Daniel Lindqvist; Oskar Hansson
Journal:  Neurology       Date:  2014-11-19       Impact factor: 9.910

Review 6.  CSF and Circulating NfL as Biomarkers for the Discrimination of Parkinson Disease From Atypical Parkinsonian Syndromes: Meta-analysis.

Authors:  Efthalia Angelopoulou; Anastasia Bougea; Andreas Papadopoulos; Nikolaos Papagiannakis; Athina-Maria Simitsi; Christos Koros; Marios K Georgakis; Leonidas Stefanis
Journal:  Neurol Clin Pract       Date:  2021-12

7.  A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.

Authors:  N K Magdalinou; R W Paterson; J M Schott; N C Fox; C Mummery; K Blennow; K Bhatia; H R Morris; P Giunti; T T Warner; R de Silva; A J Lees; H Zetterberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-01-14       Impact factor: 10.154

Review 8.  Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.

Authors:  Maria Stamelou; Gesine Respondek; Nikolaos Giagkou; Jennifer L Whitwell; Gabor G Kovacs; Günter U Höglinger
Journal:  Nat Rev Neurol       Date:  2021-08-23       Impact factor: 42.937

Review 9.  Glia and alpha-synuclein in neurodegeneration: A complex interaction.

Authors:  Dominik Brück; Gregor K Wenning; Nadia Stefanova; Lisa Fellner
Journal:  Neurobiol Dis       Date:  2015-03-10       Impact factor: 5.996

10.  Cerebrospinal fluid biomarker candidates for parkinsonian disorders.

Authors:  Radu Constantinescu; Stefania Mondello
Journal:  Front Neurol       Date:  2013-01-21       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.